Chronic Statin Administration May Attenuate Early Anthracycline-Associated Declines in Left Ventricular Ejection Function

Canadian Journal of Cardiology

Volumn 31, Issue 3, 2015, Pages 302-307

  Chotenimitkhun, Runyawan ^a   D'Agostino, Ralph ^a   Lawrence, Julia A ^a   Hamilton, Craig A ^a   Jordan, Jennifer H ^a   Vasu, Sujethra ^a   Lash, Timothy L ^b   Yeboah, Joseph ^a   Herrington, David M ^a   Hundley, W Gregory ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ATORVASTATIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; SIMVASTATIN; ANTINEOPLASTIC AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOVASCULAR MAGNETIC RESONANCE; DIABETES MELLITUS; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ATORVASTATIN CALCIUM; FEMALE; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; NEOPLASMS; PYRROLES; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84924058769     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.11.020     Document Type: Article

References (40)

1. Feola M., Garrone O., Occelli M., et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011, 148:194-198.
2. Harbeck N., Ewer M.S., De Laurentiis M., et al. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann Oncol 2011, 22:1250-1258.
3. Unverferth B.J., Magorien R.D., Balcerzak S.P., et al. Early changes in human myocardial nuclei after doxorubicin. Cancer 1983, 52:215-221.
4. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002, 360:1131-1135.
5. Coughlin S.S., Ekwueme D.U. Breast cancer as a global health concern. Cancer Epidemiol 2009, 33:315-318.
6. Drafts B.C., Twomley T.K., D'Agostino R.B., et al. Low to moderate dose anthracyline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013, 6:877-885.
7. Du X.L., Fox E.E., Lai D. Competing causes of death for women with breast cancer and change over time from 1975 to 2003. Am J Clin Oncol 2008, 31:105-116.
8. Hooning M.J., Botma A., Aleman B.M., et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. JNatl Cancer Inst 2007, 99:365-375.
9. Vasu S., Hundley W.G. Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance. JCardiovasc Magn Reson 2013, 15:66.
10. Schultz P.N., Beck M.L., Stava C., et al. Health profiles in 5836 long-term cancer survivors. Int J Cancer 2003, 104:488-495.
11. Sukel M.P., Breekveldt-Postma N.S., Erkens J.A., et al. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice. Pharmacoepidemiol Drug Saf 2008, 17:125-134.
12. Zambelli A., Della Porta M.G., Eleuteri E., et al. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast 2011, 20:176-183.
13. Truong J., Yan A.T., Cramarossa G., Chan K.K. Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can J Cardiol 2014, 30:869-878.
14. Zeglinski M., Premecz S., Lerner J., et al. Congenital absence of nitric oxide synthase 3 potentiates cardiac dysfunction and reduces survival in doxorubicin- and trastuzumab-mediated cardiomyopathy. Can J Cardiol 2014, 30:359-367.
15. Riad A., Bien S., Westermann D., et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res 2009, 69:695-699.
16. Ramasubbu K., Estep J., White D.L., et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. JAm Coll Cardiol 2008, 51:415-426.
17. Zhou Q., Liao J.K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 2009, 15:467-478.
18. Seicean S., Seicean A., Plana J.C., et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. JAm Coll Cardiol 2012, 60:2384-2390.
19. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
20. Mann D., Reynolds K., Smith D., et al. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 national Cholesterol Education Program guidelines. Ann Pharmacother 2008, 42:1208-1215.
21. Hundley W.G., Kitzman D.W., Morgan T.M., et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. JAm Coll Cardiol 2001, 38:796-802.
22. Hundley W.G., Li H.F., Hillis L.D., et al. Quantitation of cardiac output with velocity-encoded, phase-difference magnetic resonance imaging. Am J Cardiol 1995, 75:1250-1255.
23. Heckbert S.R., Post W., Pearson G.D., et al. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the multiethnic study of atherosclerosis. JAm Coll Cardiol 2006, 48:2285-2292.
24. Hundley W.G., Li H.F., Willard J.E., et al. Magnetic resonance imaging assessment of the severity of mitral regurgitation. Comparison with invasive techniques. Circulation 1995, 92:1151-1158.
25. Shehata M.L., Cheng S., Osman N.F., et al. Myocardial tissue tagging with cardiovascular magnetic resonance. JCardiovasc Magn Reson 2009, 11:55.
26. Sampath S., Derbyshire J.A., Atalar E., et al. Real-time imaging of two-dimensional cardiac strain using a harmonic phase magnetic resonance imaging (HARP-MRI) pulse sequence. Magn Reson Med 2003, 50:154-163.
27. Chaosuwannakit N., D'Agostino R., Hamilton C.A., et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. JClin Oncol 2010, 28:166-172.
28. Keefe D.L. Anthracycline-induced cardiomyopathy. Semin Oncol 2001, 28:2-7.
29. Jordan M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002, 2:1-17.
30. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
31. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007, 49:330-352.
32. Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. JClin Oncol 2003, 21:3431-3439.
33. Moser E.C., Noordijk E.M., van Leeuwen F.E., et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006, 107:2912-2919.
34. Swerdlow A.J., Higgins C.D., Smith P., et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. JNatl Cancer Inst 2007, 99:206-214.
35. Davignon J. Atherosclerosis: evolving vascular biology and clinical implications. Circulation 2004, 109:III-39-III-43.
36. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
37. Sharma H., Pathan R.A., Kumar V., et al. Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. Int J Cardiol 2011, 150:193-200.
38. Ahern T.P., Pederson L., Tarp M., et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. JNatl Cancer Inst 2011, 103:1461-1468.
39. Nickels S., Vrieling A., Seibold P., et al. Mortality and recurrence risk in relation to the use of lipid lowering drugs in a prospective breast cancer patient cohort. PLoS One 2013, 8:e75088.
40. Kalam K., Marwick T.H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2013, 49:2900-2909.